financetom
Business
financetom
/
Business
/
Eyeing 42-45% revenue growth in FY21, says ITI
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eyeing 42-45% revenue growth in FY21, says ITI
Jan 7, 2020 5:52 AM

ITI reported December quarter numbers that looked good. Revenues in the quarter grew 47 percent on a year-on-year (YoY) basis at Rs 828 crore. The company reported margins of 7.8 percent in the quarter, while in the comparable quarter of last year, it had reported an EBITDA loss. The company also reported profit after tax of Rs 168.25 crore, which includes higher other income.

Optimistic on the business outlook going forward, the Chairman and Managing Director of the company RM Agarwal said revenue target for Q4 is much higher than Q3 because total MoU target with the government of India stand at Rs 3,500 crore and the company has achieved around Rs 1,600 crore so far. They aim to achieve the rest, he said.

The revenues will be led by high value projects from BharatNet, Gujarat Net and Maharashtra Net. "The total value is two projects is around Rs 3,700 crore. Out of this Rs 3,700 crore, we shall be completing around Rs 2,000 crore from these two projects only during this financial year,” Agarwal said, adding that around Rs 400 crore turnover will come from manufacturing, while Rs 600-700 crore would come from other projects in different parts of the country through marketing, services and project unit.

Speaking about the current order book, he said, “Confirmed order book at the end of the second quarter was around Rs 7,200 crore. Already we have achieved Rs 900 crore turnover from this order book. So, around 6300-6400 crore is the remaining confirmed order book. Around Rs 7,400 crore is the order book in which we are L1.”

“We will go for 42-45 percent revenue growth in FY21 also. The same type of growth we will maintain in the next few years, as per the MoU targets,” he added.

When asked about receivables, he said, for FY19 their receivables were around Rs 2,600 crore and they have now gone up to Rs 3000 crore for FY20. The company has received around Rs 1000 crores, while the turnover is around Rs 1,600. Agarwal does not see any risk to their outstanding receivables.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved